Novo Nordisk’s stock dove 7% on Thursday just after an announcement from a key competitor. The drop came just after telehealth company Hims & Hers announced it will offer a new version of the treatment, made from the same active ingredient, semaglutide, for a fraction of Novo Nordisk’s price. The…